根据 位华尔街分析师的预测,Aspira Women's Health Inc 的收入预期范围从 $ 到 $
Aspira Women's Health Inc 的盈利质量评分是多少?
Aspira Women's Health Inc 的盈利质量评分为 /。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Aspira Women's Health Inc 何时发布财报?
Aspira Women's Health Inc 的下一份财报预计在 2026-06-24 发布
Aspira Women's Health Inc 的预期收益是多少?
根据华尔街分析师的预测,Aspira Women's Health Inc 的预期收益为 $5.25M
Aspira Women's Health Inc 是否超出收益预期?
Aspira Women's Health Inc 最近的收益为 $, 预期。
关键数据
前收盘价
$0.36
开盘价
$0.36
当日区间
$0.36 - $0.39
52周范围
$0.02 - $0.71
交易量
576
平均成交量
49.9K
股息收益率
--
每股收益(TTM)
-0.99
市值
$21.3M
什么是 AWHL?
Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.